Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Phasebio Pharmaceuticals Inc (PHAS)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 48,040,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for cardiopulmonary diseases. Co.'s primary product candidate, bentracimab, is a reversal agent for the antiplatelet drug ticagrelor. Co. is developing its preclinical product candidate, PB6440, is an aldosterone synthase inhibitor being developed for treatment-resistant hypertension. Co.'s preclinical programs include: Glucagon-like peptide-2, which stimulates growth of intestinal villi, increasing their ability to absorb nutrients and C-type natriuretic peptide, which is a regulator of bone growth and can rescue defects in fibroblast growth factor 3.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 1,795,357
Total Sell Value $0 $0 $0 $271,150
Total People Sold 0 0 0 2
Total Sell Transactions 0 0 0 2
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 85
  Page 3 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Arnold Susan Elizabeth VP, Preclinical and Chem   •       –      –    2020-10-01 4 OE $1.15 $6,236 D/D 5,423 13,152     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2020-08-21 4 OE $1.24 $12,400 D/D 10,000 119,243     -
   Sharp John P Chief Financial Officer   •       –      –    2020-08-14 4 OE $1.69 $8,450 D/D 5,000 40,000     -
   Arnold Susan Elizabeth VP, Preclinical and Chem   •       –      –    2020-02-27 4 OE $1.15 $6,236 D/D 5,423 7,729     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2019-09-06 4 OE $1.24 $23,560 D/D 19,000 109,243     -
   Sharp John P CFO and Secretary   •       –      –    2019-08-21 4 OE $1.44 $24,100 D/D 15,000 35,000     -
   Thorp Clay Director   –       •       •   2019-07-01 4 AS $14.00 $40,712 I/I (2,908) 415,959     -
   Thorp Clay Director   –       •       •   2019-06-18 4 AS $14.00 $5,600 I/I (400) 416,418     -
   Sharp John P CFO and Secretary   •       –      –    2019-05-22 4 OE $1.69 $25,350 D/D 15,000 20,000     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2019-05-20 4 OE $1.24 $23,722 D/D 19,131 90,243     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2019-05-17 4 OE $2.27 $45,203 D/D 19,913 71,112     -
   Hutson Nancy J Director   –       •      –    2018-12-17 4 B $4.46 $4,460 I/I 1,000 1,000 2.1     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2018-12-13 4 B $3.69 $3,690 I/I 1,000 51,199 2.58     -
   Ballance David James VP, Research and Sci. Affairs   •       –      –    2018-12-13 4 B $3.94 $3,940 D/D 1,000 7,600 2.66     -
   York Michael VP, Corporate Development   •       –      –    2018-12-11 4 B $3.88 $5,820 D/D 1,500 1,500 2.74     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2018-12-10 4/A B $3.85 $3,080 I/I 800 50,199 2.58     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2018-12-10 4 B $3.85 $3,080 I/I 800 51,699 2.58     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2018-12-07 4/A B $3.89 $2,723 I/I 700 49,399 2.58     -
   Sharp John P CFO and Secretary   •       –      –    2018-12-07 4 B $3.84 $19,200 D/D 5,000 5,000 2.74     -
   Mow Jonathan P Chief Executive Officer   •       •      –    2018-12-07 4 B $3.88 $8,536 I/I 2,200 50,899 2.58     -
   Thorp Clay Director   –       •       •   2018-12-04 4 B $3.13 $12,520 D/D 4,000 15,799 3.92     -
   Zeneca, Inc. 10% Owner   –       –       •   2018-10-22 4 B $5.00 $3,000,000 I/I 600,000 3,004,554 1.5     -
   Zeneca, Inc. 10% Owner   –       –       •   2018-10-22 4 A $0.00 $0 I/I 2,404,554 2,404,554     -
   Thorp Clay Director   –       •       •   2018-10-22 4 B $5.00 $1,500,000 I/I 300,000 416,481 2.25     -
   Thorp Clay Director   –       •       •   2018-10-22 4 A $0.00 $0 I/I 2,158,049 266,481     -
  85 Records found
  1  2  3  4   
  Page 3 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us